PR NewswireBOSTON, April 2, 2019 /PRNewswire/ — LumeNXT, Inc. has appointed Marc Beer Chairman of the Board. LumeNXT is a privately-held company focused on the development of a proprietary surgical illumination product line for minimally invasive surgeries. Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals, devices, and diagnostics to the new leadership role.

“I am proud to be working with such a dedicated and accomplished group of surgeons and engineers who have advanced the field of surgical illumination with the LumeNXT proprietary technology which is important to safely perform surgery,” said Marc Beer. “I believe the importance of the LumeNXT platform will increase as more surgeries are performed with minimally invasive approaches.”

Surgeons that use targeted illumination find that the technology enhances visualization, precision, and flexibility during operations, as compared to traditional techniques.

LumeNXT offers an advanced illumination platform used as a heat reduction mechanism to improve surgical precision, low-cost disposable options, and safety through enhanced visualization.

“Marc has demonstrated high levels of success in multiple startup companies that he’s guided through the multiple growth phases,” said Paul Rhyne, Co-Founder of LumeNXT. “His vast experience in starting companies and guiding them through global commercial rollout and the path to profitability is highly valued as our company grows.”

Marc Beer, the Founding Chairman and CEO of Renovia, Inc., founded the company whose mission is to discover and deliver first line digital therapeutic and diagnostic devices for women with pelvic floor disorders in August of 2016.

Prior to Renovia, Beer was the Former and Founding Chairman of Minerva Neurosciences Inc., a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Minerva is conducting multiple late-stage clinical trials as well as developing innovative therapeutic compounds for schizophrenia, insomnia and mood disorders, major depressive disorders, and Parkinson’s Disease.

Prior to Minerva, Beer held many leadership roles in the biopharmaceutical field where he was responsible for commercial launches addressing rare disease on a global scale, global growth, initial public offerings (IPOs), acquisitions and more. Some of Beer’s previous positions include; Former and Founding Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases); Founding Chairman of the board of Good Start Genetics, Inc. (recently acquired by InVitae); Former CEO of ViaCell (VIAC); acquired in 2007 by PerkinElmer; Board of Directors of Erytech Pharma; Vice President of Global Marketing at Genzyme; and various sales and marketing roles at Abbott Laboratories. Additionally, Beer was a member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.